Kiniksa Pharmaceuticals International (KNSA) EBT Margin (2021 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly EBT Margin came in at 12.79% in Q2 2026, down 180.0% YoY from 15.98% in Q2 2025, and down 16.18% on a QoQ basis from 15.25% in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) EBT Margin (2021 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 6 years of EBT Margin data on file, last reported at 12.79% in Q2 2026.
- Quarterly EBT Margin fell 180.0% year-over-year to 12.79% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 13.59% (up 1089.0% YoY) and the FY2025 annual result came in at 13.12%, up 2166.0% from the prior year.
- EBT Margin fell to 12.79% in Q2 2026, from 15.25% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 47.14% in Q3 2022 to a low of 86.37% in Q4 2023.
- A 5-year average of 12.98% and a median of 4.08% in 2023 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin soared 45491 bps — and 2023, when it slumped 5982 bps.
- Tracing KNSA's EBT Margin over 5 years: stood at 61.3% in 2022, then tumbled by 41 bps to 86.37% in 2023, then jumped by 84 bps to 13.86% in 2024, then soared by 183 bps to 11.51% in 2025, then grew by 11 bps to 12.79% in 2026.
- The last three EBT Margin figures came in at 12.79% (Q2 2026), 15.25% (Q1 2026), and 11.51% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | -10.99% |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 35.09% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 13.34% |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 47.58% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -1.70% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 16.91% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 4.09% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.07 Bn | 5.54 Bn | 220.03 Mn | 12.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.79% |
| Mar 31, 2026 | 15.25% |
| Dec 31, 2025 | 11.51% |
| Sep 30, 2025 | 15.02% |
| Jun 30, 2025 | 14.59% |
| Mar 31, 2025 | 11.30% |
| Dec 31, 2024 | -13.86% |
| Sep 30, 2024 | -6.42% |
| Jun 30, 2024 | 2.12% |
| Mar 31, 2024 | -17.88% |
| Dec 31, 2023 | -86.37% |
| Sep 30, 2023 | -12.68% |
| Jun 30, 2023 | -1.73% |
| Mar 31, 2023 | -19.37% |
| Dec 31, 2022 | -61.30% |
| Sep 30, 2022 | 47.14% |
| Jun 30, 2022 | -71.43% |
| Mar 31, 2022 | -72.34% |
| Dec 31, 2021 | -233.66% |
| Sep 30, 2021 | -253.51% |